Anticonvulsant derivative salts

• US 7,098,188 B2
• Filed: 07/03/2002
• Issued: 08/29/2006
• Est. Priority Date: 07/09/2001
• Status: Expired due to Term

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Inventors: Abdel-Magid, Ahmed, Maryanoff, Cynthia
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): McIntosh, III, Traviss C.
• Application Number:
  US10/188,924
• Publication Number:
  US 20030069190A1
• Time in Patent Office: 1,518 Days
• Field of Search: 514/23, 514/454, 514/455, 514/459, 514/463, 536/1.11, 536/18.7
• US Class Current: 514/23
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: C07H 11/00 Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof halo-sugars C07H5/02; thio-, seleno-, or telluro-sugars C07H5/08

Abstract

The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.

Claims

1. A crystalline sodium or potassium salt of a compound of formula (I)

2. The salt as in claim 1, wherein the compound of formula (I) is topiramate having the following structure:

3. A salt as in claim 2, of the formula (II)

4. The salt as in claim 3, characterized essentially by the following X-ray diffraction pattern:

5. The salt as in claim 3, characterized essentially by the following X-ray diffraction pattern:

6. The salt as in claim 3, characterized essentially by the following X-ray diffraction pattern:

7. The salt as in claim 3, characterized essentially by the following X-ray diffraction pattern:

8. The salt as in claim 2, of the formula (III)

9. The salt as in claim 8, characterized essentially by the following X-ray diffraction pattern:

10. The salt as in claim 8, characterized essentially by the following X-ray diffraction pattern:

11. The salt as in claim 8, characterized essentially by the following X-ray diffraction pattern:

12. The salt as in claim 8, characterized essentially by the following X-ray diffraction pattern:

13. A pharmaceutical composition comprising a salt of claim 1 and a pharmaceutically acceptable carrier.

14. A process for making a pharmaceutical composition comprising combining a salt of claim 1 with a pharmaceutically acceptable carrier.

15. A process for preparing a sodium or potassium salt of a compound of formula (I) comprising

reacting a compound of formula (I)

16. The process as in claim 15, wherein the hydride is sodium hydride, the hydroxide is sodium hydroxide, the lower alkoxide is sodium lower alkoxide or the amide is sodium amide.

17. The process as in claim 15, wherein the hydride is potassium hydride, the hydroxide is potassium hydroxide, the lower alkoxide is potassium lower alkoxide or the amide is potassium amide.

18. The process as in claim 15, wherein the compound of formula (I) is topiramate having the following structure:

19. The process as in claim 16, wherein the compound of formula (I) is topiramate having the following structure:

20. The process as in claim 17, wherein the compound of formula (I) is topiramate having the following structure: